Livforsakringsbolaget Skandia Omsesidigt maintained its position in shares of Allergan PLC. (NYSE:AGN) during the second quarter, Holdings Channel reports. The institutional investor owned 21,910 shares of the company’s stock at the end of the second quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Allergan PLC. were worth $5,326,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in AGN. GWM Advisors LLC increased its position in shares of Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after buying an additional 5 shares during the period. JNBA Financial Advisors increased its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the period. Tarbox Group Inc. increased its position in shares of Allergan PLC. by 0.6% in the first quarter. Tarbox Group Inc. now owns 2,393 shares of the company’s stock valued at $572,000 after buying an additional 15 shares during the period. Jacobi Capital Management LLC increased its position in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the period. Finally, WFG Advisors LP increased its position in shares of Allergan PLC. by 4.1% in the first quarter. WFG Advisors LP now owns 656 shares of the company’s stock valued at $157,000 after buying an additional 26 shares during the period. 84.77% of the stock is currently owned by institutional investors.

Allergan PLC. (AGN) traded up 0.29% during midday trading on Friday, reaching $232.88. The company’s stock had a trading volume of 1,820,899 shares. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The firm has a market capitalization of $77.85 billion, a PE ratio of 7.10 and a beta of 1.16. The stock’s 50-day moving average price is $245.93 and its 200 day moving average price is $238.13.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the previous year, the firm posted $3.35 EPS. Allergan PLC.’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities analysts anticipate that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/13/livforsakringsbolaget-skandia-omsesidigt-has-5326000-stake-in-allergan-plc-agn.html.

A number of research firms have recently issued reports on AGN. UBS AG reissued a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a research report on Monday, May 15th. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target on the stock in a research report on Monday, June 26th. Wells Fargo & Company reissued an “outperform” rating and set a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a research report on Wednesday. Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a research report on Wednesday, May 10th. Finally, Royal Bank Of Canada increased their price target on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 10th. Eight investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $274.49.

In other news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.